FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Haemonetics Corporation HAE

Mixed   broader-coverage candidate · Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital.

On FrontierLab's discovery record since 2026-06-18 (9 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-01), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)-2%
Gross margin57.3%
Gross profits / assets0.32
Rule of 4016.2
Net margin18.2%
Cash runway (months)
PEG
Price / sales2.9

Quality checklist

Fundamentals — snapshot as of 2026-08-01

StageEstablished
Share issuance (YoY)-6.6% · buying back shares
Moat
TAM
P/E (trailing)42.3
EPS (trailing)$2.02
Burn multiple
Gross-margin trend (pts)2
Cash / assets0.1
Net debt / EBITDA3.5
Statements as ofQ4 FY2026 · filed 2026-05-20

Momentum context — a snapshot from 2026-08-01, not current

Price at surface$85.54 (as of 2026-08-01)
52-week range$47.32 – $87.32
% off 52-wk high-2%
RSI (14)74
Relative volume1.1×

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-01 (end-of-day). How grades are computed →